Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...

Pfizer said it will 'support capacity-building initiatives, such as training healthcare professionals and advancing clinical ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

Pfizer PFE will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus ...

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

In 2024, companies in the broader market that paid dividends returned around 35% of their net income and 45% of their free ...

GSK and Pfizer’s full-year financial results show that the former is currently winning the battle for take-up of their rival respiratory syncytial virus (RSV) vaccines, although, there are signs ...

Vaccinating pregnant women against RSV reduced the risk of infection in their infants by 61% compared with newborns with ...

RSV is also a problem in infants ... handing an advantage to Pfizer, which already has data showing Abrysvo is effective and could get a decision from the FDA on that use in August.

ABRYSVO now offers the broadest RSV vaccine indication for adults, which previously included thos NEW YORK, October 15, 2024--Pfizer Inc. (NYSE: PFE) today announced the election of Mortimer ("Tim ...

No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...